TXG 10x Genomics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest 10x Genomics, Inc. (TXG) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 13, 2026, a 10-Q quarterly report filed on November 7, 2025, an 8-K current report filed on February 12, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for 10x Genomics, Inc. (TXG) (SEC CIK 1770787), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: integrated life sciences technology products and software for analyzing biological systems with high resolution and scale
- • New acquisition in 2025: Scale Biosciences, adding QuantumScale single cell RNA and methylation kits to single cell portfolio
Risk Factors
- • Regulatory/legal risk: Patent litigation settlements with Vizgen (Feb 2025, $26M upfront) and Bruker (May 2025, $68M installments) impacting license and royalty revenue
- • Geopolitical/macroeconomic risk: Foreign currency fluctuations affecting revenue, mainly in euro, GBP, and JPY markets, causing realized/unrealized gains/losses of $4.6M in 2025
Management Discussion & Analysis
- • Revenue and profitability details not disclosed in provided text
- • No segment performance data included
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New acquisition risk from Scale Biosciences asset acquisition in August 2025 with $20M technology transfer payment due Q1 2026 and up to $30M contingent consideration
- • Material update on patent litigation settlements with Vizgen and Bruker, generating total $94M upfront with gain on settlements boosting first-half 2025 revenues
Annual Reports Archive10-K
AI-powered analysis of 10x Genomics, Inc. (TXG) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of 10x Genomics, Inc. (TXG) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | — | $618.7M | $610.8M | $642.8M |
| Gross Profit | — | $409.3M | $414.5M | $443.9M |
| Operating Income | — | -$265.3M | -$194.6M | -$61.0M |
| Net Income | — | -$255.1M | -$182.6M | -$43.5M |
| Gross Margin | — | 66.2% | 67.9% | 69.1% |
| Op. Margin | — | -42.9% | -31.9% | -9.5% |
| Net Margin | — | -41.2% | -29.9% | -6.8% |
| Balance Sheet | ||||
| Total Assets | $1.0B | $965.1M | $918.6M | $1.0B |
| Equity | $805.7M | $741.0M | $710.1M | $796.3M |
| ROE | — | -34.4% | -25.7% | -5.5% |
Source: XBRL financial data from 10x Genomics, Inc. (TXG) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
10-K | Feb 13, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 12, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Nov 7, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 8, 2025 | Jun 30, 2025 | — | |
10-Q | May 9, 2025 | Mar 31, 2025 | — | |
10-K | Feb 13, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 29, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | Apr 30, 2024 | Mar 31, 2024 | — | |
10-K | Feb 15, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 3, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 4, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Feb 16, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Feb 18, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 5, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 6, 2021 | Jun 30, 2021 | — | |
10-Q | May 7, 2021 | Mar 31, 2021 | — | |
10-K | Feb 26, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 12, 2020 | Sep 30, 2020 | — | |
10-Q | Aug 12, 2020 | Jun 30, 2020 | — |
Frequently Asked Questions
What are the latest TXG SEC filings in 2026?
10x Genomics, Inc. (TXG) has filed a 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 7, 2025, an 8-K current report on February 12, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did TXG file its most recent 10-K annual report?
10x Genomics, Inc. (TXG) filed its most recent 10-K annual report on February 13, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view TXG 10-Q quarterly reports?
10x Genomics, Inc. (TXG)'s most recent 10-Q quarterly report was filed on November 7, 2025. SignalX displays every TXG 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has TXG filed recently?
10x Genomics, Inc. (TXG)'s most recent 8-K was filed on February 12, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find TXG insider trading activity (Form 4)?
SignalX aggregates every TXG Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does TXG file with the SEC?
10x Genomics, Inc. (TXG) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TXG filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for 10x Genomics, Inc. (TXG).
What is TXG's SEC CIK number?
10x Genomics, Inc. (TXG)'s SEC CIK (Central Index Key) number is 1770787. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1770787 to look up all TXG filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find TXG return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from 10x Genomics, Inc. (TXG) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of 10x Genomics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 28+ filings.